Anticalins®: The lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies

Andreas M. Hohlbaum, Arne Skerra

Publikation: Beitrag in FachzeitschriftÜbersichtsartikelBegutachtung

20 Zitate (Scopus)

Abstract

Anticalins® are engineered ligand-binding proteins based on the human lipocalin scaffold. Their architecture is characterized by a rigid β-barrel that supports four structurally hypervarlable loops. Similar to antibodies, these loops form the natural ligand-binding site, usually for vitamins, hormones or secondary metabolites. Anticalins with novel specificities can be engineered by reshaping this loop region, using targeted random mutagenesis in combination with functional display and guided selection. Several drug candidates with specificities for exogenous low-molecular-weight substances, peptides and even protein targets (e.g., several disease-related cell surface receptors) have been obtained in this way. Owing to their exquisite specificity and high affinity, Anticalins are particularly attractive as antagonists for the manipulation of immune mechanisms, leading to either inhibitory or stimulatory effects. Compared with antibodies, Anticalins offer several practical advantages as they are much smaller, consist of a single polypeptide chain and can be produced easily in microbial expression systems.

OriginalspracheEnglisch
Seiten (von - bis)491-501
Seitenumfang11
FachzeitschriftExpert Review of Clinical Immunology
Jahrgang3
Ausgabenummer4
DOIs
PublikationsstatusVeröffentlicht - Juli 2007

Fingerprint

Untersuchen Sie die Forschungsthemen von „Anticalins®: The lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren